The results "support the safety and efficacy of the stent in iliac arteries," Dr. Clair concluded.
The DURABILITY II trial was sponsored by Covidien, the company developing the EverFlex stent. The ORION trial was sponsored by Boston Scientific, the company developing the Epic stent. Dr. Matsumura said that he has received research grants from Covidien and from Abbott, Cook, Endologix, and W.L. Gore. Dr. Clair said that he has been a consultant to Boston Scientific, and also to Covidien, Endologix, ev3, and Medtronic.